On November 25, 2025, the Centers for Medicare & Medicaid Services (CMS) announced significant price reductions for 15 high-cost prescription drugs used by millions of Medicare beneficiaries. That's a major win for older Americans.
The negotiated "maximum fair prices," made possible by the 2022 Inflation Reduction Act, promise to save the program $12 billion annually compared with last year's Medicare spending on 15 widely used drugs to treat cancer and other serious chronic conditions that hit older adults hardest.
Previously, the Biden administration reached deals to lower the costs of 10 prescription drugs, including several for heart disease and diabetes, which are set to take effect in 2026. This latest round of price negotiations will go into effect in 2027, with seniors expected to see an estimated $685 million in out-of-pocket relief.
From just $107.88 $24.99 for Kiplinger Personal Finance
Become a smarter, better informed investor. Subscribe from just $107.88 $24.99, plus get up to 4 Special Issues
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Historically, prescription drug costs have wreaked havoc on many seniors' budgets, with some rationing doses or skipping their meds altogether due to high costs, according to a survey by research group KFF.
For the roughly 5.3 million Medicare beneficiaries who take these 15 medications, and the new $2,100 annual out-of-pocket cap in Medicare Part D, starting in 2026, 2027 can’t come soon enough.
For decades, Medicare was prohibited by law from negotiating drug prices directly with manufacturers, resulting in older Americans paying two to four times what patients in Europe or Canada paid for the same medicines.
Seniors like 72-year-old retiree Ryan Whitworth of Florida, who relies on Xtandl for prostate cancer, could see his monthly copays halved. “Finally, I won’t have to choose between meds and groceries,” he told Kiplinger.
Below is the full list of the 15 drugs and their new Medicare maximum fair prices compared with the 2024 list prices. All figures are for a typical 30-day supply. The numbers are rounded to the nearest dollar where applicable.
Drug Name | Commonly Treated Conditions | 2024 List Price | 2027 Medicare Price | % Reduction |
Ozempic; Rybelsus; Wegovy | Type 2 diabetes; Type 2 diabetes & cardiovascular disease; Cardiovascular disease & obesity/overweight | $959 | $274 | -71% |
Trelegy Ellipta | Asthma; Chronic obstructive pulmonary disease | $654 | $175 | -73% |
Xtandi | Prostate cancer | $13,480 | $7,004 | -48% |
Pomalyst | Kaposi sarcoma; Multiple myeloma | $21,744 | $8,650 | -60% |
Ofev | Idiopathic pulmonary fibrosis | $12,622 | $6,350 | -50% |
Ibrance | Breast cancer | $15,741 | $7,871 | -50% |
Linzess | Chronic idiopathic constipation; irritable bowel syndrome with constipation | $539 | $136 | -75% |
Calquence | Chronic lymphocytic leukemia/small lymphocytic lymphoma; Mantle cell lymphoma | $14,228 | $8,600 | -40% |
Austedo; Austedo XR | Chorea in Huntington’s disease; Tardive dyskinesia | $6,623 | $4,093 | -38% |
Breo Ellipta | Asthma; Chronic obstructive pulmonary disease | $397 | $67 | -83% |
Xifaxan | Hepatic encephalopathy; Irritable bowel syndrome with diarrhea | $2,696 | $1,000 | -63% |
Vraylar | Bipolar 1 disorder; Major depressive disorder; Schizophrenia | $1,376 | $770 | -44% |
Tradjenta | Type 2 diabetes | $488 | $78 | -84% |
Janumet; Janumet XR | Type 2 diabetes | $526 | $80 | -85% |
Otezla; Otezla XR | Oral ulcers in Behçet’s Disease; Plaque psoriasis; Psoriatic arthritis | $4,722 | $1,650 | -65% |
The “2024 List Price” column shows the gross Wholesale Acquisition Cost (WAC) that Medicare Part D plans were charged in 2024 for a 30-day supply, before any rebates or discounts.
The “2027 Medicare Price” column is the Maximum Fair Price (MFP) manufacturers must offer Medicare starting January 1, 2027, for a 30-day supply.
Sources: CMS, November 2025 (pdf); Medicare prescription drug affordability fact sheet; Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability, Year 2027 (pdf)
List prices reflect typical Part D gross costs before rebates.
Related content
- 16 Strategies to Save Money on Prescription Drugs
- Here Are the 10 Medicare Negotiated Drug Prices
- Medicare to Cover Obesity Drugs Under Trump Deal for as Little as $50. What You Need to Know
- Seven Medicare Changes Coming in 2026
- Brace for Higher Health Costs in 2026: A Look at Projected Medicare Premiums
-
Is a New $25,000 Health Care Tax Deduction Coming in 2026?Tax Policy A proposal from GOP Sen. Josh Hawley is adding to the chatter about health care affordability.
-
Are You Middle-Class? Here's The Most Tax-Friendly State For Your FamilyTax Tips We found the state with no income tax, low property tax bills, and exemptions on groceries and medicine.
-
Should You Tap Your Home Equity Before 2026?As borrowing rates and tax law shifts converge, here's what homeowners need to know before pulling equity out of their home.
-
My Adult Child Was Laid Off. Can We Discuss It Without Ruining the Holidays?We asked mental health and financial experts for advice.
-
Three Year-End Tax Strategies for Retirees With $2 Million to $10 MillionTo avoid the OBBB messing up your whole tax strategy, get your Roth conversions and charitable bunching done by year's end.
-
'Politics' Is a Dirty Word for Some Financial Advisers: 3 Reasons This Financial Planner Vehemently DisagreesYour financial plan should be aligned with your values and your politics. If your adviser refuses to talk about them, it's time to go elsewhere.
-
For a Move Abroad, Choosing a Fiduciary Financial Planner Who Sees Both Sides of the Border Is CriticalWorking with a cross-border financial planner is essential to integrate tax, estate and visa considerations and avoid costly, unexpected liabilities.
-
Average Retirement Income by Age and StateWhether you are already retired or just beginning to save, these age and state income averages offer a critical reality check to retirement savings and spending plans.
-
5 Year-End Moves to Maximize Your 2025 Retirement SavingsRetirement planning is about consistency, commitment and making the most of every dollar. Here are five high-impact moves to ensure long-term growth.
-
I'm a Financial Adviser: This Tax Trap Costs High Earners Thousands Each YearMutual funds in taxable accounts can quietly erode your returns. More efficient tools, such as ETFs and direct indexing, can help improve after-tax returns.
-
Is 2026 Your Year To Retire?Say yes to retirement if you can answer these questions.
